Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Operating Income: 2009-2025

Historic Operating Income for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $34.3 million.

  • Amicus Therapeutics' Operating Income rose 58.22% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 529.46%. This contributed to the annual value of $24.9 million for FY2024, which is 132.22% up from last year.
  • Amicus Therapeutics' Operating Income amounted to $34.3 million in Q3 2025, which was up 461.72% from -$9.5 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Operating Income high stood at $34.3 million for Q3 2025, and its period low was -$75.3 million during Q1 2022.
  • Moreover, its 3-year median value for Operating Income was -$8.0 million (2025), whereas its average is -$3.2 million.
  • In the last 5 years, Amicus Therapeutics' Operating Income soared by 532.58% in 2024 and then slumped by 163.30% in 2025.
  • Amicus Therapeutics' Operating Income (Quarterly) stood at -$72.1 million in 2021, then spiked by 41.33% to -$42.3 million in 2022, then skyrocketed by 91.28% to -$3.7 million in 2023, then soared by 532.58% to $16.0 million in 2024, then skyrocketed by 58.22% to $34.3 million in 2025.
  • Its Operating Income was $34.3 million in Q3 2025, compared to -$9.5 million in Q2 2025 and -$8.0 million in Q1 2025.